Profile data is unavailable for this security.
About the company
Race Oncology Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on improving the lives of cancer patients around the world by developing a novel approach to both treating the cancer and protecting the heart. Its lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. It is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations. It is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia.
- Revenue in AUD (TTM)832.58k
- Net income in AUD-13.82m
- Incorporated2011
- Employees--
- LocationRace Oncology LtdLevel 36, Gateway 1, Macquarie PlaceSYDNEY 2000AustraliaAUS
- Phone+61 28051-3043
- Websitehttps://www.raceoncology.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Race Oncology Ltd | 832.58k | -13.82m | 243.78m | -- | -- | 13.30 | -- | 292.80 | -0.0839 | -0.0839 | 0.0051 | 0.1075 | 0.0355 | -- | 0.9201 | -- | -58.97 | -46.49 | -63.04 | -48.68 | -- | -- | -1,659.82 | -2,995.74 | -- | -- | 0.00 | -- | 40.68 | 116.86 | -39.26 | -- | -- | -- |
| Pell Bio Med Technology Co Ltd | 848.56k | -19.04m | 244.64m | -- | -- | 3.78 | -- | 288.30 | -8.02 | -8.02 | 0.341 | 23.77 | 0.0132 | 10.43 | 4.23 | -- | -29.90 | -- | -34.86 | -- | -113.22 | -- | -2,262.16 | -- | 7.19 | -- | 0.0985 | -- | 5.11 | -- | -73.27 | -- | -- | -- |
| Jacobio Pharmaceuticals Group Co Ltd | 4.91m | -76.71m | 253.72m | 298.00 | -- | 1.33 | -- | 51.63 | -0.5008 | -0.5008 | 0.0321 | 1.23 | 0.016 | -- | 2.41 | 82,741.46 | -24.89 | -45.76 | -28.66 | -49.30 | 3.45 | -- | -1,560.88 | -372.22 | -- | -- | 0.1794 | -- | -33.66 | -- | 3.43 | -- | 19.18 | -- |
| Mabpharm Ltd | 32.14m | -43.86m | 272.62m | 297.00 | -- | 11.17 | -- | 8.48 | -0.0539 | -0.0539 | 0.0395 | 0.03 | 0.164 | 0.1937 | 3.26 | 469,376.20 | -22.38 | -21.42 | -31.11 | -27.49 | 86.91 | -- | -136.47 | -486.40 | 0.6836 | -22.44 | 0.679 | -- | 55.87 | -- | 0.694 | -- | -26.85 | -- |
| Imugene Ltd | 0.00 | -149.68m | 275.22m | 0.00 | -- | 2.29 | -- | -- | -0.0211 | -0.0211 | 0.00 | 0.0162 | 0.00 | -- | -- | -- | -85.91 | -44.42 | -95.62 | -47.46 | -- | -- | -- | -- | -- | -- | 0.0053 | -- | -- | -- | -294.78 | -- | 136.28 | -- |
| Pharma Foods International Co., Ltd. | 617.61m | 31.85m | 280.02m | 642.00 | 8.54 | 2.35 | 6.85 | 0.4534 | 113.47 | 113.47 | 2,185.12 | 412.69 | 1.71 | 2.10 | 14.00 | 96,802,180.00 | 8.81 | 8.63 | 25.38 | 22.06 | 78.45 | 80.64 | 5.16 | 4.13 | 0.8875 | 81.16 | 0.5933 | 27.65 | -9.37 | 42.62 | 4.02 | 45.01 | 28.23 | -- |
